News - Anti-virals, ViiV Healthcare

Filter

Popular Filters

1 to 25 of 27 results

ViiV Healthcare links with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

ViiV Healthcare links with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

12-06-2014

ViiV Healthcare today announced that they have entered into an agreement with Janssen R&D Ireland, a…

Anti-viralsEdurantGlaxoSmithKlineJanssenJohnson & JohnsonLicensingPharmaceuticalResearchTivicayViiV Healthcare

IQWIG finds added benefit in adult patients for VIIV Healthcare’s Tivicay

27-05-2014

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG),…

Anti-viralsGermanyGlaxoSmithKlinePharmaceuticalPricingRegulationTivicayViiV Healthcare

ViiV Healthcare grants licence to Medicines Patent Pool to improve access to Tivicay

ViiV Healthcare grants licence to Medicines Patent Pool to improve access to Tivicay

02-04-2014

Viiv Healthcare, the HIV/AIDS joint venture of UK pharma giant GlaxoSmithKline, US drugmaker Pfizer and…

Anti-viralsGlobalPharmaceuticalPricingTivicayViiV Healthcare

Putting patients first is a win-win situation

Putting patients first is a win-win situation

07-02-2014

Here's our take on the week's top stories.

Anti-viralsPharmaceuticalTivicayUKViiV Healthcare

IN FOCUS: Viiv Healthcare’s Tivicay offers new HIV treatment option for patients

IN FOCUS: Viiv Healthcare’s Tivicay offers new HIV treatment option for patients

03-02-2014

Global HIV company Viiv Healthcare has launched its first new treatment option for people with HIV today.

Anti-viralsAtriplaInterviewsIsentressPharmaceuticalPrezistaRegulationResearchTivicayUKViiV Healthcare

ViiV Healthcare’s new HIV medicine Tivicay is approved in Europe

21-01-2014

The European Commission has approved Tivicay (dolutegravir) made by Viiv Healthcare for use in combination…

Anti-viralsEuropePharmaceuticalResearchTivicayViiV Healthcare

Tivicay set to become leading HIV treatment by 2016

Tivicay set to become leading HIV treatment by 2016

15-01-2014

Antiretroviral drug Tivicay (dolutegravir) is set to become the leading integrase inhibitor for the treatment…

Anti-viralsAsia-PacificEuropeIsentressJanssenMarkets & MarketingMerck & CoPharmaceuticalPrezistaTivicayUSAViiV Healthcare

Mixed US court decision on ViiV Healthcare’s Epzicom and Trizivir patents

19-12-2013

UK pharma giant GlaxoSmithKline and ViiV Healthcare confirmed that the US District Court for the District…

Anti-viralsEpzicomGenericsGlaxoSmithKlineLegalLupinPatentsTeva Pharmaceutical IndustriesTrizivirViiV Healthcare

ViiV Healthcare’s Tivicay approved in Canada for HIV

04-11-2013

ViiV Healthcare, the HIV/AIDS joint venture set up by UK pharma giant GlaxoSmithKline with US behemoth…

Anti-viralsdolutegravirGlaxoSmithKlineNorth AmericaPfizerPharmaceuticalRegulationShionogiTivicayViiV Healthcare

ViiV Healthcare presents positive Tivicay results from HIV study

13-09-2013

Positive data has been reported from the Phase IIIb/IV FLAMINGO study of Tivicay (dolutegravir) versus…

Anti-viralsNorth AmericaPharmaceuticalResearchTivicayViiV Healthcare

In wake of Tivicay approval, MSF asks, "when will people in developing countries have access?"

13-08-2013

As the US Food and Drug Administration approved the new HIV drug Tivicay (dolutegravir) late Monday (The…

Anti-viralsdolutegravirGlobalHealthcarePharmaceuticalPricingTivicayViiV Healthcare

FDA approves new ViiV Healthcare HIV drug

13-08-2013

The US Food and Drug Administration yesterday (August 12) approved Tivicay (dolutegravir), a new drug…

Anti-viralsdolutegravirGlaxoSmithKlineNorth AmericaPfizerPharmaceuticalRegulationShionogiTivicayViiV Healthcare

Medicines Patent Pool and ViiV Healthcare collaborate to treat pediatric HIV

28-02-2013

The Medicines Patent Pool (MPP) this week announced the launch of a new collaboration with ViiV Healthcare…

AbacavirAnti-viralsGenericsGlobalPatentsPharmaceuticalViiV Healthcare

Briefs: Roche deal with Chiasma; Vasella payout; FDA priority review for dolutegravir

18-02-2013

Swiss drug major Roche (ROG: SIX) has entered into an agreement to develop and commercialize privately…

Anti-viralsdolutegravirGlaxoSmithKlineLicensingManagementNovartisOctreotide AcetatePharmaceuticalRare diseasesRegulationRocheViiV Healthcare

Sales of antiretroviral agents for HIV will decline slightly over next decade

18-12-2012

Major-market sales of antiretroviral (ARV) agents for HIV will decline slightly over the next decade,…

Anti-viralsBiotechnologydolutegravirGenericsGlaxoSmithKlineGlobalMarkets & MarketingPharmaceuticalRegulationViiV Healthcare

ViiV Healthcare's dolutegravir shows promise in hard-to-treat HIV patients

16-11-2012

ViiV Healthcare, and HIV/AIDS company jointly owned by GlaxoSmithKline (LSE: GSK), Pfizer (NYSE: PFE)…

Anti-viralsdolutegravirGlaxoSmithKlinePfizerPharmaceuticalResearchShionogiViiV Healthcare

Revised terms for ViiV Healthcare and Shionogi HIV partnership

30-10-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) says that Healthcare, its HIV/AIDS joint venture with Pfizer,…

Anti-viralsdolutegravirGlaxoSmithKlineMergers & AcquisitionsPfizerPharmaceuticalShionogiViiV Healthcare

Shionogi-Viiv Healthcare to start regulatory filing of dolutegravir by year-end

08-10-2012

Shionogi-ViiV Healthcare, a joint venture between Japan's Shionogi (TYO: 4507) and ViiV Healthcare, a…

Anti-viralsdolutegravirGlaxoSmithKlinePfizerPharmaceuticalRegulationResearchShionogiShionogi-ViiV HealthcareViiV Healthcare

ViiV and Shionogi say dolutegravir meets primary endpoint in HIV

02-04-2012

ViiV Healthcare, the HIV/AIDS joint venture of UK drugs giant GlaxoSmithKline (LSE: GSK) and US behemoth…

Anti-viralsdolutegravirGlaxoSmithKlinePfizerPharmaceuticalResearchShionogiViiV Healthcare

Mylan gets tentative FDA approval for generic Epzicom

23-02-2012

US generics major Mylan (Nasdaq: MYL) says that its subsidiary Mylan Laboratories has received tentative…

Anti-viralsEpzicomGenericsGlaxoSmithKlineMylan LaboratoriesNorth AmericaPfizerRegulationViiV Healthcare

ViiV Healthcare announces 16 new grantees for 2011/2012 to prevent mother-to-child HIV transmission

13-10-2011

ViiV Healthcare, the HIV/AIDS joint venture of UK drugs giant GlaxoSmithKline (LSE: GSK) and US behemoth…

Anti-viralsFinancialGlaxoSmithKlineHealthcarePfizerPharmaceuticalRest of the WorldViiV Healthcare

1 to 25 of 27 results

Back to top